Why did Vistagen's operating expenses drop sharply in Q1 2024?

Vistagen's operating expenses dropped sharply in Q1 2024 primarily due to the timing of expenses incurred for the Phase 3 trials of fasedienol in SAD. The company's research and development expenses decreased to $4.5 million from $6.9 million in the same quarter last year. This reduction was a result of the timing of the expenses, not a reduction in the overall expenses.